<DOC>
	<DOCNO>NCT00902668</DOCNO>
	<brief_summary>RATIONALE : Drugs , lovastatin , may protect normal cell side effect radiation therapy . PURPOSE : This phase II trial study well lovastatin work reduce side effect radiation therapy woman breast cancer .</brief_summary>
	<brief_title>Lovastatin Reducing Side Effects After Radiation Therapy Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine incidence good/excellent cosmetic outcome , define Harvard Scale , radiotherapy woman treat lovastatin , compare historical control . OUTLINE : Patients undergo standard external beam whole-breast irradiation and/or accelerate partial breast irradiation . Patients receive oral lovastatin daily begin first day radiotherapy continue 12 month absence disease progression unacceptable toxicity . Patients complete questionnaire , Breast Cancer Treatment Outcome Scale , baseline 6 month , 12 month , 3 year completion radiotherapy ass cosmetic functional outcome . After completion radiotherapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis invasive situ epithelial cancer breast Stage 0 , I , II ( Tis , T1 , T2 ) disease Unifocal disease ( single focus encompass breastconserving surgery ) Has undergone prior surgical resection primary lesion ( lumpectomy ) axillary nodal evaluation ( invasive disease present ) Negative surgical margin ( ≥ 1 mm ) Planning undergo radiotherapy either standard external beam radiotherapy accelerate partial breast irradiation ( interstitial balloon brachytherapy ) No Paget disease nipple No evidence distant metastases Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Karnofsky performance status 70100 % Transaminases &lt; 3 time upper limit normal ( ULN ) Creatine kinase &lt; 5 time ULN Creatinine clearance ≥ 30 mL/min Negative pregnancy test No active liver muscle disease No history collagen vascular disease ( e.g. , systemic lupus erythematosus , scleroderma , dermatomyositis ) History prior malignancy allow provided life expectancy ≥ 4 year No major medical psychiatric illness , investigator 's opinion , would prevent completion study treatment interfere followup No contraindication HMGcoAreductase inhibitor PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy breast , lung , mediastinum Prior radiotherapy contralateral breast allow No chemotherapy ≥ 2 week prior , , ≥ 2 week completion radiotherapy No concurrent cytochrome P450 3A4 inhibitor Concurrent HMGcoAreductase inhibitor allow provided patient able switch 20 mg lovastatin per day Concurrent tamoxifen aromatase inhibitor allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>